Moreover, targeted therapy with BRAF blocker (e.g., vemurafenib and dabrafenib) or MEK inhibitors (e.g., cobimetinib and trametinib) has shown promising results in refractory LCH [103, 105, 106]. Here, BRAF is linked to Langerhans cell histiocytosis.